Virtual Library
Start Your Search
S. Ikeda
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-031 - Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy in Completely Resected Lung Cancer (ID 8829)
09:30 - 09:30 | Author(s): S. Ikeda
- Abstract
Background:
S-1 is one of the key-drugs as chemotherapy for the non-small cell lung cancer (NSCLC). We conducted a multicenter randomized study of adjuvant S-1 administration schedules for surgically treated pathological stage IB-IIIA NSCLC patients.
Method:
Patients receiving curative surgical resection were centrally randomized to arm A (4 weeks of oral S-1 and a 2-week rest over 12 months) or arm B (2 weeks of S-1 and a 1-week rest over 12 months). The primary endpoints were total days of administration, and the secondary endpoints were relative total administration dose (relative dose intensity), toxicity, and 3-year disease-free survival. Total days of administration were evaluated according to the cumulative rates of total S-1 administration days within 224 days, at the end of 12 months. Relative dose intensity was defined as (the actual total dose administered divided by the planned total administered dose) × 100.
Result:
From April 2005 to January 2012, 80 patients were enrolled, of whom 78 patients were eligible and assessable. The cumulative rates of total S-1 administration days at the end of 12 months, were 81.3% for arm A (38 cases) and 60.2% for arm B patients (40 cases, p = 0.04). The relative dose intensity was 77.2% for arm A and 58.4% for arm B (p = 0.01). Drug-related grade 3 adverse events were recorded for 11% of arm A and 5% of arm B (p = 0.43). The 3-year disease-free survival rate was 79.0% for arm A and 79.3% for arm B (p = 0.94). Toxicity showed no significant difference among the shorter schedule and the conventional schedule, except for grade 1-3 elevation of bilirubin.
Conclusion:
The superiority of feasibility of the shorter schedule was not recognized in the present study. The conventional schedule showed higher cumulative rates of total S-1 administration days at the end of 12 months (p = 0.04) and relative dose intensity of S-1 (p = 0.01).
-
+
P3.16 - Surgery (ID 732)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.16-022 - Surgery for Non-Small-Cell Lung Cancer with Malignant Minor Pleural Effusion Detected on Thoracotomy (ID 8970)
09:30 - 09:30 | Author(s): S. Ikeda
- Abstract
Background:
Surgery is usually not indicated for malignant pleural effusion due to its poor prognosis. However, malignant pleural effusion is first detected at thoracotomy (malignant minor pleural effusion), and it is difficult to judge an appropriate mode of resection. Several reports have demonstrated that the prognosis of patients with malignant pleural effusion first detected at thoracotomy is relatively favorable, aggressive surgical approaches may result in long-term survival. In some cases long-term survival is expected for malignant pleural disease unless the causal tumor is highly responsive to systemic chemotherapy. The aim of this study is to describe the results of surgical intervention in NSCLC patients with malignant minor pleural effusion.
Method:
We retrospectively studied 21 surgical patients with NSCLC and malignant minor pleural effusion that is found during thoracotomy, from January 1989 till March 2017. Surgical-pathological staging was carried out according the 7th edition of the TNM classification of lung cancer. We examined the clinicopathological features, the current status of therapy, and surgical outcomes in patients with malignant minor pleural effusion.
Result:
The median survival time and 5-year survival rate in the 21 patients were 16.9 months and 19.3%. Primary tumor resection was perfomed in 20 patinets(95.2%), pneumonectomy was 1 case, lobectomy was 14 cases, segmetectomy was 1 case and wedge resection was 4 cases. Of our 21 petients, 10 had malignant pleural nodule. The 5-year survival rate for 10 patients with malignant pleural nodule was 0%, whereas the 5-year survival rate for 11 patients without malignant pleural nodule was 30.0%. But there is no significant difference in survival between with or without malignant pleural nodule. Univariate analyses revealed that women, adenocarcinoma histology were associated with significant longer survival. 6 patients(28.6%) survive more than 3 years and 3 patients(14.3%) survive more than 5 years, all patients were adenocarcinoma, cN0.
Conclusion:
Tumor resection is beneficial for the survival of several patients with NSCLC who have a minor malignant pleural effusion. Our results warrant to the possible benefits of surgery in NSCLC patients, and to justify the inclusion of surgery in multimodality treatment of NSCLC patients with minor malignant pleural effusion.
